TITLE

Pharma sector to grow at 13%

PUB. DATE
March 2007
SOURCE
Chemical Business;Mar2007, Vol. 21 Issue 3, p78
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article offers information on a study by IndusView on the pharmaceutical industry in India. According to the study, the domestic pharmaceutical industry is expected to grow 13% and reach a market size of $6.5 billion. Topics discussed include low cost, high volume generic drugs, mergers and acquisitions, contract research and clinical trials, and increased integration with global trade.
ACCESSION #
24691627

 

Related Articles

  • Bulking up in generics. Mirasol, Feliza // Chemical Market Reporter;3/13/2006, Vol. 269 Issue 10, p18 

    The article reports on the mergers and acquisitions (M&A) of companies in the generic drug industry worldwide. In 2000, leading consolidations were Novartis' Sandoz, Teva Pharmaceuticals and Merck KGaA. Decision Resources Inc. cited the factors driving the boom of M&A activity including cost...

  • Novartis divests products for Hexal deal.  // Chemical Market Reporter;5/23/2005, Vol. 267 Issue 21, p20 

    The article informs that pharmaceutical firm Novartis AG is set to divest a handful of products in selected European markets as part of concessions made to gain approval from European regulatory authorities for Novartis's proposed acquisition of German generics company, Hexal AG. Novartis...

  • Best may be yet to come for generic drug makers. Kirsche, Michelle L. // Drug Store News;2/14/2005, Vol. 27 Issue 2, p28 

    Reports on the research-and-development pipeline of drug makers in the U.S. Sales of generic companies; Factors contributing to the performance of drug makers; Development of generic pipeline.

  • GPhA bullish on generic industry's future. Cohen, Harold E. // Drug Topics;5/7/2001, Vol. 145 Issue 9, p64 

    Provides information on the Generic Pharmaceutical Association (GPhA), a unification of the generic industry in the United States. Significance of the formation of a united front for the generic industry; Goals of the association; Strategy of pharmacy benefit managers.

  • Is the Generics Industry Ready for Multi-Source Biologics? Challener, Cynthia // Chemical Market Reporter;04/23/2001, Vol. 259 Issue 17, p14 

    Deals with the generic biologic industry. Estimated growth of the biopharmaceutical generics market; Details on the acquisition of Indiana Protein Technologies by Ivax Corp.; European firms preparing to participate in the marketing and sales of generic biopharmaceuticals; Risks faced by a...

  • SEE pharmaceutical market healthy in 2010. Stamov, Valentin; Pavlova, Iskra // SEE Top 100;2011, p46 

    The article focuses on the condition of the pharmaceutical market in 2010 in Southeast Europe (SEE). It notes that sales of pharmaceuticals in the SEE region are influenced by generic drugs. It claims that there is a growth in the pharmaceutical market in Bulgaria in terms of value. It also...

  • Generic Rx Has Majority of Market, IMS Study Shows. Toth, Wendy // SN: Supermarket News;3/17/2008, Vol. 56 Issue 11, p25 

    The article focuses on a study which found that generic prescriptions account for a large part of the pharmaceutical market in the U.S. According to the study, 65 percent of all U.S. prescriptions dispensed are filled with generics. It also noted that as a number of big-name drugs are set to...

  • Foe Turned Friend. Overdorf, Jason; Spring, Silvia // Newsweek (Atlantic Edition);3/5/2007 (Atlantic Edition), Vol. 149 Issue 10, p43 

    The article states that generic drug manufactures in India are teaming up with larger pharmaceutical companies. The Indian pharmaceutical companies previously have been involved in legal battles with the larger pharmaceutical companies for copying their drugs. The partnerships are due in part to...

  • Developing World to Get Cheaper Generics. Scott, Alex // Chemical Week;12/4/2002, Vol. 164 Issue 47, p48 

    Reports that trade ministers from World Trade Organization nations agreed at a meeting in Sydney, Australia in December 2002 to allow developing nations to manufacture generic drugs for export. Implication of the proposal; Criticism from aid groups.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics